Clinical Trial Update: A Study to Investigate the Efficacy and Safety of Subcutaneous Lunsekimig (SAR443765) Compared With Placebo in Adult Participants With Moderate-to-severe Atopic Dermatitis [Phase 2]

View source ↗

Summary

Phase 2 study evaluating subcutaneous Lunsekimig (SAR443765) vs placebo in adults with moderate-to-severe atopic dermatitis. The trial status is completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Atopic Dermatitis

Drugs mentioned

• Lunsekimig (Lunsekimig)

Snippet

Sponsor: Sanofi | Conditions: Dermatitis Atopic | Phase 2 | Status: COMPLETED